Skip to main content
. 2022 Sep 12;9(9):ofac473. doi: 10.1093/ofid/ofac473

Table 1.

Basic Characteristics of the Cohort, Stratified by the Composite Outcome of Recurrence or Death

Characteristic Total (N = 4624) Patients Who Had the Composite Outcome (n = 2084) Patients Who Did Not Have the Composite Outcome (n = 2540)
Age, y, mean (SD) 64.3 (11.3) 65.4 (11.3) 63.3 (11.1)
Male sex 4466 (96.6) 2016 (96.7) 2450 (96.5)
Race
 White 3391 (73.3) 1531 (73.5) 1860 (73.2)
 Black 830 (18.0) 355 (17.0) 475 (18.7)
 Other 403 (8.7) 198 (9.5) 205 (8.1)
BMI, kg/m2
 Underweight (BMI <20) 44 (1.1) 25 (1.3) 19 (0.9)
 Normal (BMI ≥20 and <25) 541 (13.2) 291 (15.6) 250 (11.2)
 Overweight (BMI ≥25 and <30) 1161 (28.4) 519 (27.8) 642 (28.8)
 Obese (BMI = 30) 2346 (57.3) 1030 (55.2) 1316 (59.1)
Geographic area
 Northeast 605 (13.1) 248 (11.9) 357 (14.1)
 South 1778 (38.5) 793 (38.1) 985 (38.8)
 Central 1271 (27.5) 585 (28.1) 686 (27.0)
 West 970 (21.0) 458 (22.0) 512 (20.2)
Year of PJI
 2003–2004 401 (8.7) 202 (9.7) 199 (7.8)
 2005–2007 820 (17.7) 387 (18.6) 433 (17.1)
 2008–2010 857 (18.5) 406 (19.5) 451 (17.8)
 2011–2013 828 (17.9) 357 (17.1) 471 (18.5)
 2014–2016 820 (17.7) 354 (17.0) 466 (18.4)
 2017–2019 898 (19.4) 378 (18.1) 520 (20.5)
Joint
 Knee 3779 (81.7) 1706 (81.9) 2073 (81.6)
 Hip 813 (17.6) 362 (17.4) 451 (17.8)
Timing of PJI from previous joint surgery
 Early (within 90 d) 1150 (24.9) 445 (21.4) 705 (27.7)
 Late (after 90 d) 1056 (22.8) 458 (22.0) 598 (23.5)
 Unknown 2418 (52.3) 1181 (56.7) 1237 (48.7)
Modified APACHE III score
 ≤21 3276 (70.9) 1285 (61.7) 1991 (78.4)
 22–32 902 (19.5) 511 (24.5) 391 (15.4)
 33–45 341 (7.4) 209 (10.0) 132 (5.2)
 >45 105 (2.3) 79 (3.8) 26 (1.0)
Staphylococcus aureus susceptibility
 MSSA 3405 (73.6) 1456 (69.9) 1949 (76.7)
 MRSA 1219 (26.4) 628 (30.1) 591 (23.3)
 Polymicrobial infection 1111 (24.3) 485 (23.9) 626 (24.7)
Comorbidities
 Myocardial infarction 367 (8.0) 198 (9.5) 169 (6.7)
 Congestive heart failure 755 (16.4) 457 (22.0) 298 (11.8)
 COPD 1433 (31.2) 699 (33.7) 734 (29.1)
 Peripheral vascular disease 925 (20.1) 528 (25.4) 397 (15.8)
 Cerebrovascular disease 665 (14.5) 341 (16.4) 324 (12.9)
 Dementia 86 (1.9) 41 (2.0) 45 (1.8)
 Hemiplegia 160 (3.5) 98 (4.7) 62 (2.5)
 Autoimmune disease 294 (6.4) 153 (7.4) 141 (5.6)
 Diabetes mellitus 1792 (39.0) 929 (44.8) 863 (34.3)
 Peptic ulcer 253 (5.5) 137 (6.6) 116 (4.6)
 Liver disease 670 (14.6) 362 (17.4) 308 (12.2)
 Chronic kidney disease 648 (14.1) 376 (18.1) 272 (10.8)
 Solid cancer 805 (17.5) 433 (20.9) 372 (14.8)
 Hematologic malignancy 106 (2.3) 69 (3.3) 37 (1.5)
 HIV/AIDS 51 (1.1) 27 (1.3) 24 (1.0)
Duration of rifampin treatment from day 15 after DAIR
 0 d 3782 (81.8) 1742 (83.6) 2040 (80.3)
 1–90 d 610 (13.2) 290 (13.9) 320 (12.6)
 91–180 d 143 (3.1) 33 (1.6) 110 (4.3)
 181–731 d 89 (1.9) 19 (0.9) 70 (2.8)
Duration of antibiotic treatment from day 15 after DAIR
 ≤90 3602 (77.9) 1802 (86.5) 1800 (70.9)
 91–180 d 286 (6.2) 114 (5.5) 172 (6.8)
 181–270 d 164 (3.6) 62 (3.0) 102 (4.0)
 ≥271 d 572 (12.4) 106 (5.1) 466 (18.4)

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DAIR, debridement, antibiotics, and implant retention; HIV, human immunodeficiency virus; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PJI, prosthetic joint infection; SD, standard deviation.